

Inflammatory activation and endothelial dysfunction markers in patients with permanent atrial fibrillation: a cross-sectional study

Carlo Domenico Maida^{1,4}, Sonya Vasto^{2,*}, Domenico Di Raimondo^{1,*}, Alessandra Casuccio³, Valerio Vassallo¹, Mario Daidone¹, Alessandro Del Cuore¹, Gaetano Pacinella¹, Anna Cirrincione¹, Irene Simonetta¹, Vittoriano Della Corte⁴, Salvatore Rizzica¹, Giulio Geraci⁵, Antonino Tuttolomondo^{1,**}, Antonio Pinto^{1,**}

¹U.O.C di Medicina Interna con Stroke Care, Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, University of Palermo, Palermo, Italy

²Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, University of Palermo, Palermo, Italy

³Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro” Section of Public Health Epidemiology and Preventive Medicine, University of Palermo, Palermo, Italy

⁴Molecular and Clinical Medicine PhD Programme, University of Palermo, Palermo, Italy

⁵Unit of Nephrology and Hypertension, European Society of Hypertension Excellence Center, Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, University of Palermo, Palermo, Italy

* Co-second authors

**Co-senior authors

Correspondence to: Carlo Domenico Maida; email: carlodomenico.maida@unipa.it

Keywords: atrial fibrillation, cytokines, inflammation, endothelial dysfunction, structural heart disease

Received: October 2, 2019

Accepted: April 16, 2020

Published: May 3, 2020

Copyright: Maida et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

In recent years a growing body of evidence supported the role of inflammation in the initiation, maintenance and outcome of atrial fibrillation (AF). Nevertheless, despite a large amount of information, whether AF or the underlying structural heart disease (SHD) is the cause of the inflammatory process is still under debate. We, therefore, sought to determine if the inflammatory process reflect an underlying disease or the arrhythmia ‘per se’. We evaluated plasma levels of soluble Interleukin 2 Receptor Alpha (sIL-2R α), TNF- α and IL-18 in 100 consecutive patients with permanent AF, (43 with a SHD and 57 without a SHD) compared to 121 age and sex-matched controls which had normal sinus rhythm. We also evaluated the endothelial function in both groups of patients using reactive hyperemia index (RHI) values measured by Endo-PAT2000. Compared to controls, AF patients showed higher circulating levels of inflammatory markers and a lower mean value of RHI. At multiple logistic regression analysis, the inflammatory markers and RHI were significantly associated with AF presence, whereas ROC curve analysis had good sensitivity and specificity in inflammatory variables and RHI for AF presence. No significant association was observed in the group of permanent AF patients, between inflammatory markers and the presence of an underlying SHD. These findings could help to clarify the role of inflammation in subjects with AF and suggest that the markers of systemic inflammation are not associated with the underlying cardiovascular disease, rather with the atrial fibrillation ‘per se’.

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac rhythm disorder and it represents one of the major causes of heart failure, stroke, sudden death and cardiovascular morbidity worldwide [1]. In recent years, several studies [2–4] have described a strong association between AF and inflammation, suggesting the key role of the inflammatory process in the initiation, maintenance and outcome of the arrhythmia itself. Multiple inflammatory markers and mediators have been found to be elevated in patients with AF, including C-reactive protein (CRP), interleukin (IL)-2, IL-6, IL-8, monocyte chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)- α . Furthermore, inflammatory infiltrates compatible with a diagnosis of myocarditis (lymphomononuclear infiltrates) has been demonstrated by several studies [5, 6] performing atrial and ventricular endomyocardial biopsies in patients with "lone AF" (LAF), suggesting the histological inflammatory substrate of this arrhythmia.

Nevertheless, despite a large amount of information, whether the cause of the inflammation is the arrhythmia itself or the underlying structural heart disease (SHD) is still under debate. Only a few studies [7, 8] investigated this field assessing the circulating levels of CRP mostly in subjects with LAF and with SHD, without clarifying if this marker is associated with the AF 'per se' or rather with the underlying cardiovascular disease. Besides, these studies have investigated the inflammatory pathway of atrial fibrillation patients only by determine CRP plasma levels, and in recent years numerous evidence [9] suggest to avoid the use of the historical term "lone AF".

Considering the active link between the arrhythmia and the inflammatory process, reported by previous studies [2–6], we hypothesized that the inflammatory activation of AF subjects may represent the mirror of the arrhythmia 'per se', regardless of the presence of an underlying abnormality of heart structure. We, therefore, aimed to investigate patients with permanent AF and compared their "inflammatory cytokines milieu" to that of controls in sinus rhythm evaluating the association between inflammatory markers and underlying SHD.

Furthermore, in recent years AF has been associated with endothelial dysfunction [10, 11]. Besides, accumulating evidence supports the role of inflammatory cytokines in endothelial dysfunction [12]. Thus, the purpose of the study was also to assess the endothelial function in our AF cohort compared to controls in sinus rhythm, through the use of reactive hyperemia peripheral arterial tonometry (RH-PAT), and

to evaluate the relationship between inflammatory variables and this vascular health marker.

RESULTS

A total of 100 subjects with permanent AF and 121 control subjects in sinus rhythm without any history of AF, were enrolled. General and laboratory characteristics of patients with AF and of subjects in sinus rhythm and without any history of AF are listed in Table 1. Among AF patients 47 (%) had a SHD while 53 (%) had no SHD. Characteristics and differences of AF patients with and without SHD are listed in Table 2. Subjects with AF showed in comparison to subjects without AF a significantly higher frequency of hypertension (84 vs 58.08%; $p < 0.001$) and diabetes mellitus (34% vs 30.25%; $p < 0.019$), higher mean cholesterol blood levels (148.94 ± 40.13 mmol / L vs 133.74 ± 35.17 mmol / L; $p < 0.003$), higher mean HbA1c blood levels (6.16 ± 1.15 vs 5.31 ± 1.44 ; $p < 0.001$), higher mean microalbuminuria values (95.56 ± 39.77 vs 61.94 ± 31.73 ; $p < 0.025$) and higher mean left atrium diameter (45.99 ± 9.05 vs 38.47 ± 7.57 ; $p < 0.001$). Subjects with AF had lower mean heart rate values (80.01 ± 16.64 bpm vs 88.15 ± 12.39 bpm; $p < 0.001$), lower mean SBP values (127.33 ± 15.57 mmHg vs 131.28 ± 10.45 mmHg; $p < 0.026$), lower mean left ventricular ejection fraction values ($50.39 \pm 11.29\%$ vs $55.58 \pm 9.40\%$; $p < 0.001$) and a lower mean value of RHI (1.76 ± 0.83 vs. 2.34 ± 0.68 ; $p = 0.001$) (Figure 1). Regarding of inflammatory markers, AF patients had higher plasma values of IL 18 (442.72 ± 172.34 vs 172.85 ± 109.69 ; $p < 0.001$), TNF α (7.85 ± 3.05 vs 2.99 ± 0.97 ; $p < 0.001$) and sIL-2R α (867.22 ± 391.40 vs 276.28 ± 95.82 ; $p < 0.001$) compared with controls (see Figure 1). Subjects with AF and SHD showed in comparison to AF subjects with NSHD a significantly higher mean age (77.5 ± 9.3 vs 70.4 ± 13.3 ; $p = 0.003$) and higher mean left atrium diameter (53.9 ± 6.9 vs 38.9 ± 2.5 ; $p < 0.005$). Subjects with AF and SHD had lower mean left ventricular ejection fraction values ($39.5 \pm 4.4\%$ vs $60 \pm 4.9\%$; $p < 0.0005$) and a lower mean value of RHI (1.5 ± 0.4 vs. 2 ± 1 ; $p = 0.002$). Regarding of inflammatory markers, AF patients with SHD had higher plasma values of TNF α (8.6 ± 1.9 vs 7.2 ± 3.7 ; $p = 0.021$) and sIL-2R α (964.9 ± 334.6 vs 782.4 ± 419.6 ; $p = 0.020$) compared with AF patients with NSHD.

A Multiple logistic regression model, including all the significant baseline variables ($P < 0.05$) predictive of AF, showed that RHI (OR=5.94; 95% CI = 0.93- 20.78; $p = 0.053$), IL- 18 (OR = 1.01; 95% CI = 1-1.019; $p = 0.042$), TNF α (OR = 5.1; 95% CI = 1.35-19.18; $p = 0.016$), sIL-2R α (OR= 1.02; 95% CI = 1.007-1.038; $p = 0.005$) and hypertension (OR = 6,8; 95%

Table 1. Demographic, clinical and laboratory variables in subjects with atrial fibrillation and in controls.

Variables	AF Patients (n=100)	Controls (n=121)	p
Age (years) (mean± SD)	73.70± 12.05	74.98±9.63	0.383
M/F	54/46	73/48	
SBP (mmHg) (mean± SD)	127.33 ± 15.57	131.28±10.45	0.026
DBP (mmHg) (mean± SD)	71.48±10.36	72.917±9.93	0.295
Weight (Kg) (mean± SD)	75.18±14.24	77.90±11.03	0.111
BMI (kg/m2) (mean± SD)	26.85±4.66	27.67±3.81	0.152
Hypertension (n/%)	84/84	48/39,66	0.001
Diabetes (n/%)	34/34	25/20,66	0.019
Dyslipidaemia (n/%)	35/35	41/33,88	0.093
SHD (n/%)	47/47	30/24,79	0.019
Heart rate (bpm) (mean± SD)	80.01±16.64	88.15±12.39	0.001
Left atrium diameter (mm) (mean± SD)	45.99±9.05	38.47±7.57	0.001
LVEF (%) (mean± SD)	50.39±11.29	55.58±9.40	0.001
Total cholesterol (mMol/L) (mean± SD)	148.94±40.13	133.74±35.17	0.003
LDL cholesterol (mMol/L) (mean± SD)	82.76±33.30	83.75±33.95	0.828
Triglycerides (mmol/L) (mean± SD)	90.52±40.67	84.46±28.57	0.196
HbA1C (mean± SD)	6.16±1.15	5.31±1.44	0.001
Micro albuminuria (mean± SD)	95.56±39.77	61.94±31.73	0.025
eGFR (ml/min) (mean± SD)	72.47± 17.09	70.70± 19.87	0.477
ACE inhibitors or ARB (n/%)	61/61	47/38,84	0.001
Beta blockade (n/%)	50/50	37/30,57	0.003
Calcium channel blockers (n/%)	26/26	33/27,27	0.477
Antiarrhythmic drugs (n/%)	27/27	9/7,43	0.001
Antiplatelet drugs (n/%)	37/37	32/26,44	0.109
Anticoagulant drugs (n/%)	53/53	1/0,82	0.001
Diuretic (n/%)	49/49	14/11,57	0.001
Statin (n/%)	34/34	37/30,57	0.665
RHI (mean± SD)	1.76±0.83	2.34±0.68	0.001
IL-18 pg/mL (mean± SD)	442.72±172.34	172.85±109.69	0.001
sIL2Ralfa pg/mL (mean± SD)	867.22±391.40	276.28±95.82	0.001
TNF-alfa pg/mL (mean± SD)	7.85±3.05	2.99±0.97	0.001

Table 2. Demographic and clinical characteristics of atrial fibrillation patients with and without SHD.

AF Patients (n=100)	SHD (n= 47)	NSHD (n= 53)	p
Age (years) (mean± SD)	77.5 ± 9.3	70.4 ± 13.3	0.003
M/F	27/20	27/26	0.515
Hypertension (n/%)	40/85,1	44/83	0.776
Diabetes (n/%)	16/34	18/33,4	0.642
Dyslipidaemia (n/%)	18/38,3	17/32,1	0.515
Weight (Kg) (mean± SD)	76.2 ± 13.9	74.2 ± 14.7	0.489
BMI (kg/m2) (mean± SD)	27.4 ± 4.9	26.3 ± 4.4	0.248
SBP (mmHg) (mean± SD)	127.0 ± 16.5	127.6 ± 14.8	0.863
DBP (mmHg) (mean± SD)	70.4 ± 11.6	72.4 ± 9.2	0.331
Heart rate (bpm) (mean± SD)	80.6 ± 16.9	79.5 ± 16.5	0.742
Echocardiographic findings			
Left atrium diameter (mm) (mean± SD)	53.9 ± 6.9	38.9 ± 2.5	<0.0005
LVEF (%) (mean± SD)	39.5 ± 4.4	60.0 ± 4.9	<0.0005
Cardiac diseases (n)			
Coronary heart disease	29		
Valvular diseases	5		
Diastolic dysfunction	9		
Dilatated Cardiomyopathy	4		

Total cholesterol (mMol/L) (mean± SD)	136.5 ± 36.0	159.9 ± 40.7	0.003
LDL cholesterol (mMol/L) (mean± SD)	78.5 ± 32.9	86.6 ± 33.5	0.225
Triglycerides (mmol/L) (mean± SD)	82.7 ± 24.6	97.5 ± 50.1	0.069
HbA1C (mean± SD)	6.4 ± 1.1	6.0 ± 1.2	0.079
Micro albuminuria (mean± SD)	135.5± 208.2	60.2 ± 87.2	0.019
RHI (mean± SD)	1.5 ± 0.4	2.0 ± 1.0	0.002
IL-18 pg/mL (mean± SD)	477.2 ± 149.1	412.1 ± 186.7	0.059
sIL2Ralfa pg/mL (mean± SD)	964.9 ± 334.6	782.4 ± 419.6	0.020
TNF-alfa pg/mL (mean± SD)	8.6 ± 1.9	7.2 ± 3.7	0.021
ACE inhibitors or ARB (n/%)	31/65,9	30/56,6	0.339
Beta blockade (n/%)	29/61.7	21/39.6	0.028
Calcium channel blockers (n/%)	9/19.14	17/32	0.141
Antiarrhythmic drugs (n/%)	12/25.5	15/28.3	0.805
Antiplatelets drugs (n/%)	25/53.1	12/22.6	0.002
Anticoagulant drugs (n/%)	27/57.4	26/49	0.401
Diuretic (n/%)	31/65	18/33.9	0.001
Statin (n/%)	18/38.3	16/30.2	0.393

CI = 2.1-20.98; $p = 0.003$) were independently associated with the arrhythmia (Table 3). Moreover ROC curves identified the best cut-offs of RHI (AUC =0.772; $p = 0.0001$; sensitivity =65%, specificity

= 85%, cut-off value ≤ 1.75), IL-18 (AUC=0.906; $p= 0.0001$; sensitivity = 81%, specificity = 97.52%, cut-off value> 269.9), TNF- α (AUC = 0.904, $p = 0.0001$; sensitivity = 80%, specificity = 99.17%, cut-off value>




Figure 1. Plasma values of sIL-2R α , IL-18, TNF- α and RHI values in atrial fibrillation subjects vs. controls. (A) Plasma values of sIL-2R α in atrial fibrillation subjects compared with controls. **(B)** Plasma values of IL-18 in atrial fibrillation subjects compared with controls. **(C)** RHI values in atrial fibrillation subjects compared with controls. **(D)** Plasma values of TNF- α in atrial fibrillation subjects compared with controls.

Table 3. Multivariable logistic regression analysis of variables predictive of atrial fibrillation.

Variables	OR*	95% Confidence interval	p
IL-18	1.01	1-1.019	0.042
sIL2Ralfa	1.02	1.007-1.038	0.005
TNF-alfa	5.1	1.35-19.18	0.016
Hypertension	6.8	2.1-20.98	0.003
RHI	5.94	0.93-20.78	0.053
Micro albuminuria	1.03	1-1.05	0.007
Heart rate	0.83	0.72-0.95	0.015
Antiarrhythmic drugs	5.36	1.67-27.07	0.03
Diuretics	7.9	1.92-33.07	0.021

*adjusted data for BMI, dyslipidemia, diabetes, ACE inhibitors or ARB, Beta blockade, SBP and DBP.

5, 55), sIL-2R α (AUC = 0.895; p = 0.0001; sensitivity = 74.75%, specificity = 100%, cut-off value > 511) for the presence of AF (Figure 2).

Multiple logistic regression analysis considering the relationship between inflammatory variables and SHD showed that sIL2Ralfa (OR= -1.84; 95% CI 0.99-1; p =0.276), TNF- α (OR= -1.75; 95% CI 0.92-1.03; p =0.286) and IL-18 (OR= -1.84; 95% CI 0.99-1; p =0.66) were not associated with the SHD presence (Table 4). At multiple logistic regression analysis of the

relationship between inflammatory variables and vascular health markers such as RHI we found that sIL2Ralfa (OR=7.607; 95% CI=0.99-1; p <0.001), TNF- α (OR=7.106; 95% CI 0.39-0.91; p <0.01) and IL-18 (OR= 7.61; 95% CI 0.99-1; p =0.001) were associated with lower RHI values (RHI<2) (Table 5).

DISCUSSION

In our study, we found that the "inflammatory cytokines milieu" (in our study defined as elevated IL-18, sIL-2R α




Figure 2. Area under ROC curve, sensitivity and specificity of sIL-2R α , IL-18, TNF- α and RHI in atrial fibrillation subjects. (A) Area under ROC curve, sensitivity and specificity of reactive hyperaemia index (RHI) in atrial fibrillation subjects. **(B)** Area under ROC curve, sensitivity and specificity of IL-18 in atrial fibrillation subjects. **(C)** Area under ROC curve, sensitivity and specificity of sIL-2R α in atrial fibrillation subjects. **(D)** Area under ROC curve, sensitivity and specificity of TNF- α in atrial fibrillation subjects.

Table 4. Multivariable logistic regression of inflammatory variables predictive of SHD in atrial fibrillation patients.

AF with SHD	Variables	OR*	95% Confidence interval	p
	IL-18	-1.84	0.99-1	0.66
	sIL2Ralfa	-1.84	0.99-1	0.276
	TNF-alfa	-1.75	0.92-1.3	0.286

*adjusted data for BMI, dyslipidemia, diabetes, ACE inhibitors or ARB, Beta blockade, SBP and DBP.

Table 5. Multivariable logistic regression of inflammatory variables predictive of RHI<2 in atrial fibrillation patients.

Variables	OR*	95% Confidence interval	p
IL-18	7.61	0.99-1	0.001
sIL2Ralfa	7.607	0.992-0.998	0.001
TNF-alfa	7.106	0.39-0.91	0.019

*adjusted data for BMI, dyslipidemia, diabetes, ACE inhibitors or ARB, Beta blockade, SBP and DBP.

and TNF- α) of permanent AF subjects is significantly associated with arrhythmia but not with an underlying cardiovascular disease. To date, only a few studies have tried to address whether AF or the underlying SHD is the cause of the inflammatory response. For example, in the study conducted by Ellinor et al. [7] authors showed that patients with AF and hypertension had higher circulating CRP levels, compared with those of healthy controls (no AF group) and those of patients with LAF. Nevertheless, no differences were reported between patients with LAF and healthy controls regarding CRP levels, and therefore authors assumed that systemic inflammation is not associated with the AF itself, but rather with the underlying SHD. In another study, Pellegrino et al. [8] found that AF patients with underlying cardiovascular disease had higher CRP levels than LAF subjects. However, CRP levels in LAF patients were higher than those seen in healthy controls, suggesting that inflammation could be related to both conditions (AF and SHD). These studies investigated the inflammatory pathway of AF patients only by determining CRP plasma levels, but growing evidence suggests that the "inflammatory milieu" documented in AF subjects is more complex and involves various inflammatory markers, other than CRP [2–4].

Moreover, in consideration of our current state of knowledge, to date, the use of the historical term 'lone AF' is not recommended [9] and current guidelines [1] do not mention it. Unlike previous studies, we sought to assess more extensively the inflammatory process of AF patients with and without an underlying SHD.

Considering that our cohort consisted of patients with permanent AF, we sought to investigate the circulating levels of inflammatory markers related to this clinical subtype of AF.

Accumulating evidence supports the notion that tumor necrosis factor-alpha (TNF- α) is involved in the pathogenesis of chronic AF [18]. TNF- α plays paramount roles in atrial remodeling, including structural, electrical, contractile, and autonomic remodeling and higher TNF- α concentrations have been reported [19] in patients with persistent and permanent AF than in patients with paroxysmal AF supporting the contributes of this proinflammatory cytokine in the development of permanent forms.

Interleukin (IL)-18 is a pleiotropic proinflammatory cytokine with a central role in the inflammatory cascade. Besides, Interleukin-18 can induce TNF- α and IL-6 production by murine macrophages [20], and it can also enhance the expression of matrix metalloproteinases (MMPs) [21].

Higher levels of Interleukin-18 have been reported [22] in persistent AF patients than in paroxysmal ones supporting that interleukin-18 can mediate repair and remodeling of myocardium through increasing MMPs activity.

IL-2 is a proinflammatory cytokine that is primarily produced by activated CD4+ T cells, CD8+ T cells, and dendritic cells. There are scarce data on the relationship between IL-2 and AF [23]. The interleukin-2 (IL-2) receptor complex is an $\alpha\beta\gamma$ trimer, in which all three chains are in contact with the ligand. The α subunit of this complex, IL-2R α is a 55-kilodalton transmembrane glycoprotein with only 13 amino acids of 351 located on the cytoplasmic side of the membrane. The function of the sIL-2R α is unclear, but increased levels of the soluble IL-2R α in biological fluids reportedly correlate with increased immune system activation suggesting that it is a reliable biomarker for disease activity in inflammatory disorders [24].

However, the circulating concentration of sIL-2R α has not been reported in patients with AF, and thus, in this study, we sought to determine whether sIL-2R α was associated with AF.

Our data suggest that systemic inflammation (in terms of IL-18, sIL-2R α , and TNF- α) is not associated with the underlying SHD, but rather with the arrhythmia "per se." This finding is further confirmed by our logistic regression analysis showing no relationship between inflammatory markers such as selected cytokines serum levels and SHD.

We assume that this finding is attributable to the extremely peculiar nature of the arrhythmia that is able to induce many changes, consistent with a substantial cellular insult caused by excessively rapid activation. These include the oxidative injury of myofibrillar proteins in atrial myocytes, cellular myolysis, cardiomyocyte apoptosis and a local myocardial inflammation followed by a structural and electrophysiological remodeling which increase the persistence of AF itself [6, 25, 26]. To the best of our knowledge, this is a novel finding that further emphasizes the strong relationship between arrhythmia with the inflammatory process independently of underlying abnormality of heart structure.

We also reported that subjects with permanent AF had higher mean serum values of inflammatory cytokines in comparison to control subjects in sinus rhythm and without any history of AF. This finding suggests the presence of inflammatory activation in AF patients and is consistent with the growing evidence linking inflammation to AF [2]. It should be considered that our AF patients had a higher prevalence of some comorbidities such as hypertension, diabetes, and dyslipidemia. Furthermore, the percentage of patients taking antiarrhythmic drugs, anti-coagulants or diuretic is considerably higher in the AF cohort. The possible contribution of these conditions and pharmacological intervention in modulating the inflammatory process should be taken into account in interpreting these results. However, our findings on multinomial analysis concerning the significant association between the inflammatory markers and the arrhythmia corroborate the strong linking between the inflammatory process and AF. Moreover, ROC curve analysis had good sensitivity and specificity of inflammatory cytokines to predict AF, and this further emphasizes the hypothesis that the inflammatory process is closely connected to AF.

In comparison to control subjects without arrhythmia, we also found that subjects with AF have an endothelial function impairment, and this result confirms what was previously reported in several studies [10, 11].

Associated co-morbidities such as hypertension, diabetes, and hypercholesterolemia were prevalent in our AF subjects. It is acknowledged that the presence of these co-morbid conditions may still be contributory to endothelial dysfunction and the influence of these conditions on our findings cannot be entirely discounted, although our multiple logistic regression analysis showed a significant association between the arrhythmia and RHI. Furthermore, on ROC curve analysis, there was also had a good sensitivity and specificity of RHI for AF presence.

Although our study could not prove a cause and effect relationship between AF and endothelial dysfunction, there are several pathogenic and plausible mechanisms for the connection. A possible pathogenetic explanation is that AF is characterized by rapid and uncoordinated atrial activity, causing ineffective atrial contraction with resultant turbulent flow both in the left atrium and systemically. Indeed, loss of shear stress, as occurs in conditions of turbulent flow, is associated with decreased endothelial nitric oxide synthase (eNOS) expression as compared with laminar or pulsatile flow conditions [27]. Another suggestive hypothesis is related to the higher degree of systemic inflammation observed in permanent AF subjects. According to this hypothesis, circulating inflammation mediators such as TNF- α and IL-18 that are strongly implicated with endothelial dysfunction and cardiovascular disease [28–30] might induce vascular damage and exacerbate the atherosclerotic burden leading to higher cardiovascular morbidity and mortality that is seen in AF subjects [1]. This finding is further confirmed by our logistic regression analysis showing that inflammatory markers were associated with lower RHI values (RHI<2). Moreover, no study has examined endothelial function using reactive hyperemia peripheral arterial tonometry (RH-PAT) in a cohort of permanent AF subject; thus, our finding appears original.

Our study provides further evidence about the pivotal role of the inflammatory process in subjects with AF and suggest that the "inflammatory milieu" observed in patients with AF is the mirror of the arrhythmia 'per se', regardless of the presence of an underlying SHD.

Besides this, our findings suggest possible practical consequences in terms of emphasizing the use of drugs with pleiotropic and anti-inflammatory effects such as statins and renin-angiotensin- system (RAS)-inhibitors to modulate inflammatory pathways in AF subjects to prevent the arrhythmia and the complications related to it. The possible role of inflammation as a guide to conventional or anti-inflammatory therapy is further sustained by recent studies [31–34] that highlight the strong association of inflammation with cardiovascular

events and its influence on the pathogenesis of the vascular disease. Definite conclusions cannot be drawn at this point and randomized controlled trials are needed to clarify these issues, but the idea that inflammation markers may be used as a guide to therapy is fascinating and reasonable.

Limitations

This study is limited by the variability in medication used between AF subjects and controls. The cross-sectional analysis is a limitation since it does not allow conclusions on cause-effect relationships and the relatively small sample size may also limit conclusions. In our study subjects with AF showed higher levels of HbA1c, cholesterol and microalbuminuria compared with controls. To date, several studies suggest an association of inflammatory markers with urinary albumin excretion in the microalbuminuric range in type 2 diabetic and nondiabetic individuals and the association of worse glycemic and lipid control and greater systemic inflammation in the diabetic population. Moreover, inflammation plays a key role in all stages of the formation of vascular lesions included endothelial dysfunction. Therefore it is possible that these parameters are correlated with both inflammation and endothelial function.

MATERIALS AND METHODS

Between March 2016 and October 2017, all consecutive patients with permanent AF admitted to our ward of Internal Medicine for a new episode of dysrhythmia or other conditions not related to arrhythmia, were enrolled in this study. The diagnosis of AF was made based on at least one 12-lead electrocardiogram and according to the current guidelines [1]. Patients with AF of >12 months in duration and ≥ 1 attempt at electrical cardioversion to restore normal sinus rhythm were considered to have permanent AF.

Hypertension was defined according to the 2013 ESH/ESC guidelines [13]. Type 2 diabetes mellitus was determined using a clinically based algorithm that considered age at onset, presenting weight and symptoms, family history, onset of insulin treatment, and history of ketoacidosis [14]. Hypercholesterolemia was defined as total serum cholesterol ≥ 200 mg/dL, and hypertriglyceridemia as total serum triglyceride ≥ 150 mg/dL on the basis of the National Cholesterol Education Program–Adult Treatment Panel III reports [15].

Among AF subjects, the presence of a structural heart disease (SHD) was defined by the following characteristics: valvular heart disease, hypertrophic

cardiomyopathy, dilated cardiomyopathy, coronary artery disease, systolic dysfunction, diastolic dysfunction and key structural alterations such as left ventricular hypertrophy (LVH) and left atrial enlargement (LAE) these last two defined by the presence of a left atrial volume index (LAVI) >34 mL/m² or a left ventricular mass index (LVMI) ≥ 115 g/m² for males and ≥ 95 g/m² for females according to the ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [16]. Subjects free from the above-mentioned characteristics were considered without SHD.

As controls, among the consecutive subjects admitted to our ward between March 2016 and March 2018, we enrolled those who were matched to AF patients on the basis of age and gender, but in sinus rhythm and without any history of AF. Exclusion criteria were neoplasia, rheumatologic disorders (e.g., rheumatoid arthritis), other chronic inflammatory disease or a history of hospitalization, infection, or acute inflammatory illness within the past 6 weeks.

For AF subjects and controls we evaluated medical history, 12-lead ECG, and two-dimensional and pulsed Doppler echocardiography at admission.

Clinical and laboratory assessment

Blood samples were collected from the antecubital vein after 10 minutes of rest in the supine position. In the AF cohort blood samples were withdrawn while the patients were in AF rhythm. We evaluated circulating plasma levels of soluble Interleukin 2 Receptor Alpha (sIL-2R α), TNF- α and IL-18. sIL-2R α and TNF- α were measured in plasma by ELISA (R&D Systems, Minneapolis, MN, USA); IL-18 were measured using a commercial sandwich ELISA (MBL, Medical and Biological Laboratories Co., Ltd, Nagoya, Japan). The minimum detectable concentrations for the diagnostic tests are: sIL-2R α : 312 – 20,000pg/mL; IL-18: 12.5 pg/ml; TNF- α : 0.191 pg/mL. Intraassay and interassay coefficients of variation were: sIL-2R α : 5,11-7,59%; IL-18: 10 -15 %; TNF- α 5.2-8.5%

Rh-pat

The principle of RH-PAT has been described previously by researchers [17]. Briefly, a blood pressure cuff was placed on 1 upper arm, while the contralateral arm served as a control. PAT probes were placed on 1 finger of each hand. After a 5-min equilibration period, the cuff was inflated to 60 mm Hg above the systolic pressure or 200 mm Hg for 5 min and then deflated to induce reactive hyperemia. The RH-PAT data were digitally analyzed online (Endo-PAT2000 software

version 3.0.4). The RH- PAT index reflects the extent of reactive hyperemia and was calculated as the ratio of the average amplitude of PAT signal over 1 min starting 1.5 min after cuff deflation (control arm, A; occluded arm, C) divided by the average amplitude of the PAT signal of a 2.5-min time period before cuff inflation (baseline) (control arm, B; occluded arm, D). Thus RH-PAT index (RHI) = (C/D)/(A/B) × baseline correction.

In this study, a standard approach was used to obtain the RHI measures. RHI values were recorded with patients in a supine and resting position. In the AF cohort, RHI measures were obtained in AF rhythm.

Statistical analysis

Statistical analysis of quantitative and qualitative data, including descriptive statistics, was performed for all items. Continuous data are expressed as mean ±SD, unless otherwise specified. Baseline differences between groups were assessed by the chi-square test or Fisher exact test, as needed for categorical variables, and by the independent Student t test for continuous parameters if the data were normally distributed. Logistic regression analysis examined the correlation between patient characteristics (independent variables), and patient groups (dependent variable) in a simple model. All variables with a p-value lower than 0.5 at univariate analysis were ran in a multivariate linear regression model and the data were adjusted for BMI, dyslipidemia, diabetes, ACE inhibitors or ARB, Beta blockade, SBP and DBP. To assess the predictive rate of different cutoff values of inflammatory cytokines and RHI indexes with regard to patient groups, a receiver operating characteristic (ROC) curve with calculations of area under the curve and 95% CI was constructed, and sensitivity and specificity values were calculated. Data were analysed by IBM SPSS Software 22 version (IBM Corp., Armonk, NY, USA). All p-values were two-sided and p<0.05 was considered statistically significant.

Abbreviations

AF: Atrial Fibrillation; SHD: Structural heart disease; LAF: Lone AF; CRP: C-reactive protein; TNF- α : Tumor necrosis factor α ; IL: Interleukin; RH-PAT: Reactive hyperemia peripheral arterial tonometry; RHI: Reactive hyperemia index; LVH: Left ventricular hypertrophy; LAE: Left atrial enlargement; LAVI: Left atrial volume index; eNOS: Endothelial nitric oxide synthase.

AUTHOR CONTRIBUTIONS

Carlo Domenico Maida: Study concept and design, analysis and interpretation, critical revision of the manuscript for important intellectual content. Sonya

Vasto: Study concept and design, analysis and interpretation, critical revision of the manuscript for important intellectual content. Domenico Di Raimondo: Study concept and design, analysis and interpretation, critical revision of the manuscript for important intellectual content. Antonino Tuttolomondo: Study concept and design, analysis and interpretation, critical revision of the manuscript for important intellectual content. Alessandra Casuccio: analysis and interpretation, critical revision of the manuscript for important intellectual content. Valerio Vassallo: acquisition of data. Mario Daidone: acquisition of data. Alessandro Del Cuore: acquisition of data. Gaetano Pacinella: acquisition of data. Anna Cirrincione: acquisition of data. Irene Simonetta: acquisition of data. Vittoriano Della Corte: acquisition of data. Geraci Giulio: acquisition of data. Salvatore Rizzica: acquisition of data. Antonio Pinto: critical revision of the manuscript for important intellectual content, study supervision.

CONFLICTS OF INTEREST

These authors declare no conflicts of interest.

REFERENCES

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, et al, and ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016; 37:2893–962. <https://doi.org/10.1093/eurheartj/ehw210> PMID:27567408
2. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. *J Am Coll Cardiol*. 2012; 60:2263–70. <https://doi.org/10.1016/j.jacc.2012.04.063> PMID:23194937
3. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. *J Cardiovasc Electrophysiol*. 2010; 21:1064–70. <https://doi.org/10.1111/j.1540-8167.2010.01774.x> PMID:20455973
4. Pinto A, Tuttolomondo A, Casuccio A, Di Raimondo D, Di Sciacca R, Arnao V, Licata G. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAf). *Clin Sci (Lond)*. 2009; 116:781–89. <https://doi.org/10.1042/CS20080372> PMID:18980576
5. Chimenti C, Russo MA, Carpi A, Frustaci A. Histological substrate of human atrial fibrillation. *Biomed Pharmacother*. 2010; 64:177–83.

- <https://doi.org/10.1016/j.biopha.2009.09.017>
PMID:[20006465](https://pubmed.ncbi.nlm.nih.gov/20006465/)
6. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation*. 1997; 96:1180–84.
<https://doi.org/10.1161/01.CIR.96.4.1180>
PMID:[9286947](https://pubmed.ncbi.nlm.nih.gov/9286947/)
 7. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-Reactive protein in lone atrial fibrillation. *Am J Cardiol*. 2006; 97:1346–50.
<https://doi.org/10.1016/j.amjcard.2005.11.052>
PMID:[16635609](https://pubmed.ncbi.nlm.nih.gov/16635609/)
 8. Pellegrino PL, Brunetti ND, De Gennaro L, Ziccardi L, Grimaldi M, Biase MD. Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset. *Intern Emerg Med*. 2013; 8:123–8.
<https://doi.org/10.1007/s11739-011-0557-z>
PMID:[21448687](https://pubmed.ncbi.nlm.nih.gov/21448687/)
 9. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S, Schotten U, Rienstra M. Lone atrial fibrillation: does it exist? *J Am Coll Cardiol*. 2014; 63:1715–23.
<https://doi.org/10.1016/j.jacc.2014.01.023>
PMID:[24530673](https://pubmed.ncbi.nlm.nih.gov/24530673/)
 10. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. *Thromb Res*. 2008; 122:85–90.
<https://doi.org/10.1016/j.thromres.2007.09.008>
PMID:[17996280](https://pubmed.ncbi.nlm.nih.gov/17996280/)
 11. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. *Chest*. 2007; 132:1253–58.
<https://doi.org/10.1378/chest.07-1185>
PMID:[17890461](https://pubmed.ncbi.nlm.nih.gov/17890461/)
 12. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. *Basic Res Cardiol*. 2008; 103:398–406.
<https://doi.org/10.1007/s00395-008-0733-0>
PMID:[18600364](https://pubmed.ncbi.nlm.nih.gov/18600364/)
 13. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, et al, and Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013; 31:1281–357.
<https://doi.org/10.1097/01.hjh.0000431740.32696.cc>
PMID:[23817082](https://pubmed.ncbi.nlm.nih.gov/23817082/)
 14. Redmon B, Caccamo D, Flavin P, Michels R, O'Connor P, Roberts J, Smith S, Sperl-Hillen J. Institute for Clinical Systems Improvement. *Diagnosis and Management of Type 2 Diabetes Mellitus in Adults*. 2014.
 15. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, and AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American association of clinical endocrinologists' guidelines for management of Dyslipidemia and prevention of atherosclerosis. *Endocr Pract*. 2012 (Suppl 1); 18:1–78.
<https://doi.org/10.4158/EP.18.S1.1>
PMID:[22522068](https://pubmed.ncbi.nlm.nih.gov/22522068/)
 16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, et al, and ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016; 37:2129–200.
<https://doi.org/10.1093/eurheartj/ehw128>
PMID:[27206819](https://pubmed.ncbi.nlm.nih.gov/27206819/)
 17. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. *Circulation*. 2008; 117:2467–74.
<https://doi.org/10.1161/CIRCULATIONAHA.107.748574>
PMID:[18458169](https://pubmed.ncbi.nlm.nih.gov/18458169/)
 18. Ren M, Li X, Hao L, Zhong J. Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target? *Ann Med*. 2015; 47:316–24.
<https://doi.org/10.3109/07853890.2015.1042030>
PMID:[25982799](https://pubmed.ncbi.nlm.nih.gov/25982799/)
 19. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, Darbar D. Role of inflammation and oxidative stress in atrial fibrillation. *Heart Rhythm*. 2010; 7:438–44.
<https://doi.org/10.1016/j.hrthm.2009.12.009>
PMID:[20153266](https://pubmed.ncbi.nlm.nih.gov/20153266/)
 20. Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of

- proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. *Eur J Immunol.* 2000; 30:3057–60.
[https://doi.org/10.1002/1521-4141\(200010\)30:10<3057::AID-IMMU3057>3.0.CO;2-P](https://doi.org/10.1002/1521-4141(200010)30:10<3057::AID-IMMU3057>3.0.CO;2-P)
PMID:11069090
21. Ishida Y, Migita K, Izumi Y, Nakao K, Ida H, Kawakami A, Abiru S, Ishibashi H, Eguchi K, Ishii N. The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. *FEBS Lett.* 2004; 569:156–60.
<https://doi.org/10.1016/j.febslet.2004.05.039>
PMID:15225625
22. Luan Y, Guo Y, Li S, Yu B, Zhu S, Li S, Li N, Tian Z, Peng C, Cheng J, Li Q, Cui J, Tian Y. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. *Europace.* 2010; 12:1713–18.
<https://doi.org/10.1093/europace/euq321>
PMID:20833691
23. Hak Ł, Myśliwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). *J Interferon Cytokine Res.* 2009; 29:327–32.
<https://doi.org/10.1089/jir.2008.0082.2906>
PMID:19450160
24. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. *Ann Intern Med.* 1990; 113:619–27.
<https://doi.org/10.7326/0003-4819-113-8-619>
PMID:2205142
25. Nattel S. New ideas about atrial fibrillation 50 years on. *Nature.* 2002; 415:219–26.
<https://doi.org/10.1038/415219a>
PMID:11805846
26. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. *Circulation.* 2001; 104:174–80.
<https://doi.org/10.1161/01.CIR.104.2.174>
PMID:11447082
27. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proc Natl Acad Sci USA.* 1996; 93:10417–22.
<https://doi.org/10.1073/pnas.93.19.10417>
PMID:8816815
28. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, Zhang C. Role of TNF-alpha in vascular dysfunction. *Clin Sci (Lond).* 2009; 116:219–30.
<https://doi.org/10.1042/CS20080196>
PMID:19118493
29. Rima Elhage. Hans-Gustaf Ljunggren, and Göran K. Hansson. Proatherogenic role of interleukin-18: effects on inflammation and action on vascular cells. *Cardiovasc Res.* 2012; 96:176–80.
<https://doi.org/10.1093/cvr/cvs220>
30. Sokolic J, Tokmadzic VS, Knezevic D, Medved I, Vukelic Damjani N, Balen S, Rakic M, Lanca Bastiancic A, Laskarin G. Endothelial dysfunction mediated by interleukin-18 in patients with ischemic heart disease undergoing coronary artery bypass grafting surgery. *Med Hypotheses.* 2017; 104:20–24.
<https://doi.org/10.1016/j.mehy.2017.05.009>
PMID:28673582
31. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allesie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *J Am Coll Cardiol.* 2010; 55:725–31.
<https://doi.org/10.1016/j.jacc.2009.11.040>
PMID:20170808
32. Corrado E, Rizzo M, Muratori I, Coppola G, Novo S. Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions. *Menopause.* 2008; 15:240–47.
<https://doi.org/10.1097/gme.0b013e31812e6b60>
PMID:17917609
33. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. *J Atheroscler Thromb.* 2010; 17:1–11.
<https://doi.org/10.5551/jat.2600>
PMID:20032572
34. Basili S, Loffredo L, Pastori D, Proietti M, Farcomeni A, Vestri AR, Pignatelli P, Davì G, Hiatt WR, Lip GY, Corazza GR, Perticone F, Violi F; in collaboration with ARAPACIS Study Investigators. Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. *Int J Cardiol.* 2017; 231:143-49.
<https://doi.org/10.1016/j.ijcard.2017.01.001>
PMID:28087176